PRRT: Defining the paradigm shift to achieve standardization and individualization

Journal of Nuclear Medicine

Volumn 55, Issue 11, 2014, Pages 1753-1756

  Bodei, Lisa ^a,b   Kidd, Mark ^b   Baum, Richard P ^c   Modlin, Irvin M ^b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ZENTRALKLINIK BAD BERKA   (Germany)

Author keywords

Individualization; PRRT; Standardization

Indexed keywords

LUTETIUM 177; ORPHAN DRUG; YTTRIUM 90; OCTREOTIDE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RECEPTOR;

ALGORITHM; ARTICLE; CELL PROLIFERATION; DOSIMETRY; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; INOPERABLE CANCER; METASTASIS; NEUROENDOCRINE TUMOR; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PERSONALIZED MEDICINE; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION RESPONSE; RADIOISOTOPE THERAPY; STANDARDIZATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CELL; BRONCHIAL NEOPLASMS; DISEASE FREE SURVIVAL; INTESTINAL NEOPLASMS; NEUROENDOCRINE TUMORS; NUCLEAR MEDICINE; PANCREATIC NEOPLASMS; SCINTISCANNING; STANDARDS; STOMACH NEOPLASMS;

BRONCHIAL NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; INDIVIDUALIZED MEDICINE; INTESTINAL NEOPLASMS; NEUROENDOCRINE TUMORS; NUCLEAR MEDICINE; OCTREOTIDE; PANCREATIC NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RECEPTORS, PEPTIDE; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84910617980     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.143974     Document Type: Article

References (23)

1. Bodei L, Mueller-Brand J, Baum RP, et al. Erratum to: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41: 584.
2. Kwekkeboom DJ, Kam BL, van Essen M, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;17:R53-R73.
3. Öberg K, Knigge U, Kwekkeboom D, Perren A. Neuroendocrine gastro-enteropancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl 7):vii124-vii130.
4. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124-2130.
5. Sabet A, Ezziddin K, Pape UF, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2013;54:1857-1861.
6. Campana D, Capurso G, Partelli S, et al. Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. Eur J Nucl Med Mol Imaging. 2013;40:1197-1205.
7. Kamp K, Gumz B, Feelders RA, et al. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after 177Lu-octreotate. Endocr Relat Cancer. 2013;20:825-831.
8. Frilling A, Modlin I, Kidd M, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15:e8-e21.
9. Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med. 2002;43: 610-616.
10. Bodei L, Cremonesi M, Zoboli S, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging. 2003;30:207-216.
11. Valkema R, Pauwels S, Kvols LK, et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2006;36:147-156.
12. Bushnell DL Jr., O'Dorisio TM, O'Dorisio MS, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 2010;28:1652-1659.
13. Bodei L, Cremonesi M, Grana CM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38:2125-2135.
14. Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29:2416-2423.
15. Strigari L, Konijnenberg M, Chiesa C et al. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. Eur J Nucl Med Mol Imaging. June 11, 2014 [Epub ahead of print].
16. Cremonesi M, Ferrari M, Di Dia A, et al. Recent issues on dosimetry and radiobiology for peptide receptor radionuclide therapy. Q J Nucl Med Mol Imaging. 2011;55:155-167.
17. Sandstrom M, Garske-Roman U, Granberg D, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013;54:33-41.
18. Strigari L, Benassi M, Chiesa C, Cremonesi M, Bodei L, D'Andrea M. Dosimetry in nuclear medicine therapy: radiobiology application and results. Q J Nucl Med Mol Imaging. 2011;55:205-221.
19. Parliament MB, Murray D. Single nucleotide polymorphisms of DNA repair genes as predictors of radioresponse. Semin Radiat Oncol. 2010;20:232-240.
20. Hall JS, Iype R, Senra J, et al. Investigation of radiosensitivity gene signatures in cancer cell lines. PLoS ONE. 2014;9:e86329.
21. Vaezi A, Wang X, Buch S, et al. XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2011; 17:5513-5522.
22. Modlin IM, Drozdov I, Kidd M. The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. PLoS ONE. 2013;8:e63364.
23. Sabet A, Ezziddin K, Pape UF, et al. Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. Eur J Nucl Med Mol Imaging. 2014;41:505-510.